Upcoming Events

There are currently no upcoming events,
but check back for updates.

Past Events

SFARI 2022 Human Cognitive and Behavioral Science RFA: Informational session

On February 25, 2022, SFARI held an informational session about the 2022 Human Cognitive and Behavioral Science request for applications. The session provided an overview of the RFA and its scientific priorities from SFARI senior scientist Pamela Feliciano, SFARI clinical research scientist LeeAnne Green Snyder, SFARI senior scientist Alice Luo Clayton and Clinical Research Associates deputy director Paul Wang.

SFARI 2022 Bridge to Independence Award RFA: Informational session

SFARI hosted an informational session on the 2022 Bridge to Independence Award (BTI) request for applications (RFA). The session provided a brief overview of the BTI program and its objectives from SFARI senior scientist Alice Luo Clayton and an open Q&A panel and breakout room discussions with current BTI fellows Gabriella Boulting, Marino Pagan, and Stephanie Rudolph.

Autism Rat Models Consortium RFA: Informational session

On July 26, SFARI hosted an informational session on the Autism Rat Models Consortium request for applications (RFA). SFARI senior scientist Alice Luo Clayton, and Peter Kind, director of the Simons Initiative for the Developing Brain (SIDB) at the University of Edinburgh will present the goals and objectives of this new funding opportunity and be available to answer questions from potential applicants.

What do we mean by ‘autism risk genes’?

David Ledbetter, Ph.D.
Chief Clinical Officer, Dascena

Joseph Buxbaum, Ph.D.
Director, Seaver Autism Center
Professor, Psychiatry, Neuroscience, Genetics and Genomic Sciences
Vice Chair for Research and Vice Chair for Mentoring, Psychiatry, Icahn School of Medicine at Mount Sinai

Heather Mefford, M.D., Ph.D.
Full Member, St. Jude Children’s Research Hospital

David Ledbetter and Joseph Buxbaum discussed whether there are genes for which mutations confer risk specific to autism or whether these genes are really conferring general risk of disrupted brain development. The discussion was moderated by Heather Mefford.

Small molecules, genes and antisense oligonucleotides: Industry perspectives on treatment development for ASD

Federico Bolognani, M.D., Ph.D.
Vice President, Head of Clinical Science, Axial Therapeutics

Stuart Cobb, Ph.D.
Chief Scientific Officer, Neurogene; Research Fellow, University of Edinburgh

Yael Weiss, M.D., Ph.D.
Vice President, Business Development, Ultragenyx

Randy Carpenter, M.D.
Chief Medical Officer, Rett Syndrome Research Trust; Co-Founder, Allos Pharma

Federico Bolognani, Stuart Cobb, and Yael Weiss joined a panel to discuss new industry developments on the use of small molecules, gene therapy and antisense oligonucleotides as treatment approaches for autism spectrum disorders (ASD). The panel discussion was moderated by Randall Carpenter.

  • Previous Page
  • Viewing
  • Next Page
Subscribe to our newsletter and receive SFARI funding announcements and news